Research programme: cyclin dependent kinase inhibitors - Quest PharmaTech

Alternative Names: 2127 (CDK immunomodulator) - Quest PharmaTech; ACP-2127

Latest Information Update: 28 Apr 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Quest PharmaTech
Class Antineoplastics; Macrolides
Mechanism of Action Cyclin-dependent kinase inhibitors; MTOR protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Apr 2022 No recent reports of development identified for preclinical development in Cancer in Canada
29 Nov 2018 OncoCare Therapeutics in-licenses Targeted Cancer Therapy Technology from Quest PharmaTech for USA
16 Mar 2018 Preclinical trials in Cancer in Canada (unspecified route) (Quest PharmaTech pipeline, March 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com